Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026

Cellectis (NASDAQ: CLLS) will report fourth quarter and full year 2025 financial results for the period ending December 31, 2025 on March 19, 2026 after US market close.

Rhea-AI Summary

Cellectis (NASDAQ: CLLS) will report fourth quarter and full year 2025 financial results for the period ending December 31, 2025 on March 19, 2026 after US market close. An investor conference call and webcast will follow on March 20, 2026 at 8:00 AM ET / 1:00 PM CET.

Dial-in details and a webcast link are provided for investors to access the company’s results and business update.

Argus Mar 13 session

+2.70% close to close Open Argus

Details

News Market Reaction – CLLS

In the Mar 13 session, CLLS gained 2.70%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets the timetable for Cellectis’s Q4 and full-year 2025 results on March 19, 2026...

Analysis

This announcement sets the timetable for Cellectis’s Q4 and full-year 2025 results on March 19, 2026, followed by an investor call on March 20. It follows months of administrative capital updates, a detailed 2026 strategy outline, and notable arbitration outcomes with partners. Investors may focus on how upcoming results relate to the previously stated cash runway into H2 2027, clinical milestones, and any use of the effective Form F-3 shelf when assessing future developments.

Key Figures

Earnings release date: March 19, 2026 Reporting period end: December 31, 2025 Conference call date: March 20, 2026 +5 more

Earnings release date

March 19, 2026

Q4 and full-year 2025 results after US market close

Reporting period end

December 31, 2025

Fiscal period for Q4 and full-year 2025 results

Conference call date

March 20, 2026

Investor call following Q4 and full-year 2025 release

Call time (ET)

8:00 AM ET

Investor conference call start time

Call time (CET)

1:00 PM CET

Investor conference call start time

Domestic dial-in

+1-800-579-2543

US dial-in number for earnings call

International dial-in

+1-785-424-1789

International number for earnings call

Conference ID

CLLSFY

Identifier for accessing the earnings call

Historical Context

5 past events · Latest: Mar 04

5 events

1. Mar 04

   Share capital update

   24h Move

   -2.4%

   Monthly report of total shares and voting rights as of Feb 28, 2026.

2. Feb 04

   Share capital update

   24h Move

   -1.1%

   Monthly disclosure of share count and voting rights as of Jan 31, 2026.

3. Jan 08

   Strategy and pipeline

   24h Move

   -1.6%

   Outlined 2026 strategy, key CAR-T clinical catalysts, and cash runway into H2 2027.

4. Jan 05

   Share capital update

   24h Move

   -3.1%

   Detailed total shares and voting rights as of Dec 31, 2025.

5. Dec 15

   Arbitral decision

   24h Move

   -15.2%

   Arbitral Tribunal ordered partial termination of a Servier license for UCART19 V1.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

gene-editing, cell and gene therapies

2 terms

gene-editing medical

"a clinical-stage biotechnology company using its pioneering gene-editing platform"

Gene-editing is a set of laboratory techniques that change an organism’s DNA by adding, removing or altering specific genetic instructions—think of it as editing words in a document to fix a sentence. For investors, it matters because these tools can create new treatments, improve agricultural crops or reduce manufacturing costs, potentially driving product value, regulatory risk, research milestones and long-term revenue prospects for companies involved.

cell and gene therapies medical

"to develop life-saving cell and gene therapies, today announced that it will report"

Cell and gene therapies are advanced medical treatments that aim to repair or replace damaged cells or genes within the body to treat diseases. They hold the potential to deliver long-lasting or even curative effects, similar to fixing a broken part of a machine rather than just covering up the problem. For investors, these therapies represent a rapidly growing area with the promise of transforming healthcare and creating significant market opportunities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS, NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the fourth quarter and full year 2025 ending December 31, 2025 on Thursday, March 19, 2026 after the close of the US market.

The publication will be followed by an investor conference call and webcast on Friday, March 20, 2026, at 8:00 AM ET / 1:00 PM CET. The call will include the Company’s fourth quarter and full year 2025 results and an update on business activities. Details for the call are as follows:

Dial in information:

Domestic: +1-800-579-2543
International: +1-785-424-1789
Conference ID: CLLSFY
Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1747993&tp_key=8aa72cea7f

About Cellectis
Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications. With its in-house manufacturing capabilities, Cellectis is one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish.

Cellectis’ headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more, visit www.cellectis.com and follow Cellectis on LinkedIn and X.  

For further information on Cellectis, please contact:

Media contacts:
Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93

Investor Relations contact:
Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com

Attachment

• 20260312_FY 2025 earnings call announcement_ENGLISH.pdf

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Cellectis (CLLS) release its Q4 and full year 2025 results?

Cellectis will release Q4 and full year 2025 results on March 19, 2026 after the US market close. According to the company, the publication covers the period ending December 31, 2025 and will be followed by a conference call and webcast the next day.

How can investors join the Cellectis (CLLS) earnings call on March 20, 2026?

Investors can join the earnings call via domestic and international dial-in numbers or the webcast link provided by the company. According to the company, dial-in and webcast details are available now and the call starts at 8:00 AM ET / 1:00 PM CET on March 20, 2026.

What time is the Cellectis (CLLS) investor webcast for the 2025 results?

The investor webcast is scheduled for March 20, 2026 at 8:00 AM ET / 1:00 PM CET. According to the company, the webcast follows the March 19 publication and will include the fourth quarter and full year 2025 results plus a business update.

Will Cellectis (CLLS) provide a business update during the March 20, 2026 call?

Yes, the March 20 call will include a business update in addition to financial results. According to the company, management will discuss the fourth quarter and full year 2025 results and provide an update on ongoing clinical and corporate activities.

Where is the Cellectis (CLLS) webcast link for the March 20, 2026 presentation?

The company provided a live webcast link for the March 20 presentation and investor call. According to the company, the webcast is accessible via the provided URL and will stream the discussion of fourth quarter and full year 2025 results and accompanying remarks.

What information will Cellectis (CLLS) cover in its March 19–20, 2026 reporting events?

Cellectis will disclose its fourth quarter and full year 2025 financial results and deliver a business update during the March 20 call. According to the company, the events include results publication and a conference call/webcast reviewing the company’s recent activities and performance.